Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges
S Soverini, R Bassan, T Lion - Journal of hematology & oncology, 2019 - Springer
Abstract The Philadelphia (Ph) chromosome, resulting from the t (9; 22)(q34; q11)
translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of …
translocation, can be found in chronic myeloid leukemia (CML) as well as in a subset of …
Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients
JC Hernández-Boluda, A Pereira, I Pastor-Galán… - Blood cancer …, 2018 - nature.com
Over half of chronic myeloid leukemia (CML) patients in deep molecular response do not
lose the major molecular response (MMR) after stopping treatment with tyrosine kinase …
lose the major molecular response (MMR) after stopping treatment with tyrosine kinase …
Discontinuation of tyrosine kinase inhibitors in pediatric chronic myeloid leukemia
H Shima, A Kada, A Tanizawa, I Sato… - Pediatric Blood & …, 2022 - Wiley Online Library
Background The feasibility of tyrosine kinase inhibitor (TKI) discontinuation in pediatric
chronic myeloid leukemia (CML) remains to be fully elucidated. Procedures TKI was …
chronic myeloid leukemia (CML) remains to be fully elucidated. Procedures TKI was …
Successful tyrosine kinase inhibitor discontinuation outside clinical trials—data from the population‐based Swedish chronic myeloid leukaemia registry
H Flygt, F Sandin, T Dahlén, A Dremaine… - British journal of …, 2021 - Wiley Online Library
Clinical trials show that tyrosine kinase inhibitor (TKI) treatment can be discontinued in
selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines …
selected patients with chronic myeloid leukaemia (CML). Although updated CML guidelines …
Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: A review
C Li, L Wen, J Dong, L Li, J Huang, J Yang… - Frontiers in …, 2022 - frontiersin.org
Incidence rates of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive
(Ph+) acute lymphoblastic leukemia (ALL) are lower but more aggressive in children than in …
(Ph+) acute lymphoblastic leukemia (ALL) are lower but more aggressive in children than in …
Stochastic modelling of tyrosine kinase inhibitor rotation therapy in chronic myeloid leukaemia
HJG Lindström, AS de Wijn, R Friedman - BMC cancer, 2019 - Springer
Background Resistance towards targeted cancer treatments caused by single nucleotide
variations is a major issue in many malignancies. Currently, there are a number of available …
variations is a major issue in many malignancies. Currently, there are a number of available …
Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib
PURPOSE: Tyrosine kinase inhibitors (TKIs) have dramatically improved survival for patients
with chronic myeloid leukemia (CML). No overall survival differences were observed …
with chronic myeloid leukemia (CML). No overall survival differences were observed …
[HTML][HTML] Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models
HJG Lindström, AS de Wijn, R Friedman - Computers in Biology and …, 2024 - Elsevier
Bcr-Abl1 kinase domain mutations are the most prevalent cause of treatment resistance in
chronic myeloid leukaemia (CML). Alternate resistance pathways nevertheless exist, and …
chronic myeloid leukaemia (CML). Alternate resistance pathways nevertheless exist, and …
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study
M Malagola, A Iurlo, E Abruzzese, M Bonifacio… - Cancer …, 2021 - Wiley Online Library
Abstract Background Intermittent treatment with TKIs is an option for the great majority (70%–
80%) of CML patients who do not achieve a stable deep molecular response and are not …
80%) of CML patients who do not achieve a stable deep molecular response and are not …
The polycomb BMI1 protein is co-expressed with CD26+ in leukemic stem cells of chronic myeloid leukemia
S Galimberti, S Grassi, C Baratè, F Guerrini… - Frontiers in …, 2018 - frontiersin.org
The Polycomb gene BMI1 expression exerts a negative predictive impact on several
hematological malignancies, such as acute and chronic myeloid leukemia (CML) …
hematological malignancies, such as acute and chronic myeloid leukemia (CML) …